Curated News
By: NewsRamp Editorial Staff
August 20, 2025
Calidi Biotherapeutics Prices $6M Offering to Advance Cancer Gene Therapies
TLDR
- Calidi Biotherapeutics' $6 million public offering provides investors early access to its innovative Redtail platform targeting high-unmet-need cancers with potential for significant returns.
- Calidi priced 1.47 million common stock units at $2.00 each and 1.53 million pre-funded warrant units at $1.999 each, both with Series I warrants exercisable at $2.00 per share for five years.
- Calidi's targeted therapies using engineered oncolytic viruses could revolutionize cancer treatment by delivering genetic medicines to metastatic sites, improving survival for patients with limited options.
- Calidi Biotherapeutics is pioneering enveloped oncolytic virus technology designed to evade immune clearance and deliver potent gene therapies directly to tumor sites.
Impact - Why it Matters
This development matters because Calidi Biotherapeutics represents the cutting edge of cancer treatment innovation, particularly in the challenging area of metastatic cancers that have historically been difficult to treat effectively. The company's Redtail platform technology addresses a critical gap in oncology by enabling systemic delivery of genetic medicines to distant tumor sites, potentially transforming how we treat advanced cancers. For patients with conditions like non-small cell lung cancer and ovarian cancer—diseases with limited treatment options and poor prognoses—this technology could offer new hope. The successful funding round accelerates clinical development, bringing these potentially life-saving therapies closer to patients who desperately need better treatment alternatives. Additionally, as cancer rates continue to rise globally, advancements in targeted gene therapies represent a significant step forward in personalized medicine and could ultimately reduce healthcare costs by providing more effective, targeted treatments.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company pioneering targeted therapies for genetic medicine delivery, has announced a significant $6 million underwritten public offering. The offering consists of approximately 1.47 million common stock units priced at $2.00 each and 1.53 million pre-funded warrant units at $1.999 each, both paired with Series I warrants exercisable at $2.00 per share for five years. Ladenburg Thalmann serves as the sole book-running manager, with Laidlaw & Company (U.K.) Ltd. as co-manager, positioning the company for accelerated development of its innovative cancer treatments.
The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery to metastatic cancer sites, shielding the virus from immune clearance to effectively reach tumors and deliver potent gene therapies. Calidi's lead candidate, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs. The company is also developing protected virotherapies for intratumoral administration, focusing on injectable cancer indications that could revolutionize oncology treatment approaches.
This news was distributed through TinyGems, a specialized communications platform within the Dynamic Brand Portfolio focused on innovative small-cap and mid-cap companies with significant growth potential. TinyGems provides comprehensive distribution services including access to wire solutions through InvestorWire, editorial syndication to over 5,000 outlets, enhanced press release optimization, and extensive social media reach through IBN's network, ensuring maximum visibility for groundbreaking developments in the biotech sector.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics Prices $6M Offering to Advance Cancer Gene Therapies
